Skip to main
ZURA

ZURA Stock Forecast & Price Target

ZURA Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 33%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Zura Bio is a Henderson, NV based, clinical-stage biopharmaceutical company, with their leading candidate tibulizumab showing positive results in its Phase 2 TibuSHIELD study for the treatment of hidradenitis suppurativa (HS). With a strong cash position and ongoing development in systemic sclerosis (SSc), Zura has an attractive risk/reward setup, but faces potential challenges in market competition and intellectual property risks. So while regulatory and commercial risks may inhibit approval and market penetration, positive results for tibulizumab and ongoing developments make Zura Bio's stock a promising investment.

Bears say

Zura Bio is a clinical-stage biotech company based in San Diego. With a focus on immunology and the development of novel medicines for patients with autoimmune and inflammatory diseases, their three in-licensed clinical-stage product candidates – Tibulizumab (ZB-106), Crebankitug (ZB-168), and Torudokimab (ZB-880) – aim to address serious and debilitating conditions with unmet medical need. However, their reliance on external funding and potential challenges in clinical development, regulatory approvals, and commercialization pose significant risks to the company's attainment of its projected operational runway and potential market success.

ZURA has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 33% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zura Bio Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zura Bio Ltd (ZURA) Forecast

Analysts have given ZURA a Buy based on their latest research and market trends.

According to 6 analysts, ZURA has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zura Bio Ltd (ZURA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.